Managing beta-blockers in acute heart failure: When to start and when to stop?

Current Heart Failure Reports

Volumn 7, Issue 3, 2010, Pages 110-115

  Yilmaz, Mehmet Birhan ^a   Laribi, Said ^b   Mebazaa, Alexandre ^b  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Acute heart failure; Beta blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; ESMOLOL; METOPROLOL; NEBIVOLOL; PROPRANOLOL;

ACUTE HEART FAILURE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOGENIC SHOCK; DRUG SAFETY; HEMODYNAMICS; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 77955982946     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0014-8     Document Type: Review

References (31)

1. K Dickstein A Cohen-Solal G Filippatos, et al. 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 933 989 10.1016/j.ejheart. 2008.08.005 18826876 (Published erratums appear in Eur J Heart Fail 2009, 11:110 and Eur J Heart Fail 2010, 12:416.) This article details the most recent guidelines for patients with acute and chronic heart failure. It seems recent data will bring about renovations
2. MS Nieminen M Böhm MR Cowie, et al. 2005 Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 384 416 10.1093/eurheartj/ehi044 15681577
3. JM Arnold JG Howlett P Dorian, et al. 2007 Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers Can J Cardiol 23 21 45 1:CAS:528:DC%2BD2sXjslehurs%3D 17245481
4. SA Hunt WT Abraham MH Chin, et al. 2009 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 e1 e90 10.1016/j.jacc.2008.11.013 19358937 Published erratum appears in J Am Coll Cardiol 2009, 54:2464
5. V Panfilov I Wahlqvist G Olsson 1995 Use of beta-adrenoceptor blockers in patients with congestive heart failure Cardiovasc Drugs Ther 9 273 287 10.1007/BF00878672 1:STN:280:DyaK2MzptFGkug%3D%3D 7662594
6. JJ Krukemyer 1990 Use of beta-adrenergic blocking agents in congestive heart failure Clin Pharm 9 853 863 1:STN:280:DyaK3M7gs1SqsQ%3D%3D 1980240
7. FD Hobbs 2000 Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br J Gen Pract 50 735 742 1:STN:280:DC%2BD3crgtlarsQ%3D%3D 11050792
8. P Patel DL White A Deswal 2007 Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up Am Heart J 153 515 522 10.1016/j.ahj.2007.01.037 1:CAS:528:DC%2BD2sXjsVWit7o%3D 17383287
9. MB Yilmaz M Refiker 2007 Beta blockers in systolic heart failure: do physicians need more courage? Am Heart J 154 e23 10.1016/j.ahj.2007.07.044 17967570
10. MB Yilmaz M Refiker Y Guray, et al. 2007 Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life? Int J Clin Pract 61 225 230 10.1111/j.1742-1241.2006.01157.x 1:STN:280:DC%2BD2s%2FlvFCiug%3D%3D 17263710
11. HL Haber CL Simek LW Gimple, et al. 1993 Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy? Circulation 88 1610 1619 1:STN:280:DyaK2c%2FgslSgug%3D%3D 8104738
12. SB Felix V Stangl A Kieback, et al. 2001 Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol J Cardiovasc Pharmacol 38 666 671 10.1097/00005344- 200111000-00003 1:CAS:528:DC%2BD3MXnvFSgs78%3D 11602813
13. F Triposkiadis G Giamouzis G Kelepeshis, et al. 2007 Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure Int J Clin Pharmacol Ther 45 71 77 1:CAS:528: DC%2BD2sXjsVOksrs%3D 17323786
14. K Swedberg A Hjalmarson F Waagstein I Wallentin 1980 Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy Br Heart J 44 134 142 10.1136/hrt.44.2.134 1:STN:280:DyaL3M%2FjvFWhuw%3D%3D 6107091
15. WS Colucci M Packer MR Bristow, et al. 1996 Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group Circulation 94 2800 2806 1:CAS:528:DyaK2sXlsVShtQ%3D%3D 8941105
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
17. Effect of metoprolol CR/XL in chronic heart failure 1999 Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 2001 2007 10.1016/S0140-6736(99)04440-2
18. EJ Eichhorn MR Bristow 2001 The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial Curr Control Trials Cardiovasc Med 2 20 23 10.1186/CVM-2-1-020 1:CAS:528:DC%2BD3MXos1Wmtbc%3D 11806769
19. H Krum EB Roecker P Mohacsi, et al. 2003 Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA 289 712 718 10.1001/jama.289.6.712 1:CAS:528:DC%2BD3sXht1WisLg%3D 12585949
20. M Packer MB Fowler EB Roecker, et al. 2002 Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2194 2199 10.1161/01.CIR.0000035653.72855.BF 12390947
21. M Martínez-Sellés T Datino M Alhama, et al. 2010 Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction: data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry J Cardiovasc Med (Hagerstown) 11 352 358
22. A Ben Driss JY Tabet P Meurin, et al. 2007 Role of B-type natriuretic peptide and echocardiographic indices in predicting the development of acute heart failure following beta-blocker uptitration in chronic heart failure patients with left ventricular systolic dysfunction Int J Cardiol 115 257 258 10.1016/j.ijcard.2006.01.042 16769135
23. L Tarantini G Cioffi C Opasich, et al. 2004 Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure Ital Heart J 5 441 449 15320569
24. WA Gattis CM O'Connor DS Gallup, et al. 2004 Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial J Am Coll Cardiol 43 1534 1541 10.1016/j.jacc.2003.12.040 1:CAS:528:DC%2BD2cXjs1ylu7w%3D 15120808
25. F Van de Werf J Bax A Betriu, et al. 2008 Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2909 2945 10.1093/eurheartj/ ehn416 19004841
26. ZM Chen HC Pan YP Chen, et al. 2005 Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 1622 1632 10.1016/S0140-6736(05)67661-1 1:STN:280:DC%2BD2MrptlKmug%3D%3D 16271643
27. GC Fonarow WT Abraham NM Albert, et al. 2008 Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program J Am Coll Cardiol 52 190 199 10.1016/j.jacc.2008.03.048 1:CAS:528:DC%2BD1cXosVOgu7g%3D 18617067
28. J Butler JB Young WT Abraham, et al. 2006 Beta-blocker use and outcomes among hospitalized heart failure patients J Am Coll Cardiol 47 2462 2469 10.1016/j.jacc.2006.03.030 1:CAS:528:DC%2BD28Xls1art74%3D 16781374 This subgroup analysis indicated that use of β-blockers impacts outcomes
29. G Jondeau Y Neuder JC Eicher, et al. 2009 B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode Eur Heart J 30 2186 2192 10.1093/eurheartj/ehp323 1:CAS:528:DC%2BD1MXhtFOqu7%2FJ 19717851 This is the first randomized trial of β-blockers in patients with acute heart failure designating noninferiority of continuing option
30. A Mebazaa MS Nieminen GS Filippatos, et al. 2009 Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE Eur J Heart Fail 11 304 311 10.1093/eurjhf/hfn045 1:CAS:528: DC%2BD1MXksVOgsLo%3D 19158152 According to this article, β-blockers seem to keep in with levosimendan contrary to dobutamine
31. M Metra S Nodari A D'Aloia, et al. 2002 Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol J Am Coll Cardiol 40 1248 1258 10.1016/S0735-1097(02)02134-4 1:CAS:528:DC%2BD38Xot1WgsLg%3D 12383572